NovelStem International Corp. (NSTM)
USD 0.01
(23.46%)
USD 0.01
(23.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12 Thousand USD | 0.0% |
| 2022 | 12 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2013 | 424.75 Thousand USD | -31.08% |
| 2012 | 616.33 Thousand USD | -83.65% |
| 2011 | 3.76 Million USD | -5.64% |
| 2010 | 3.99 Million USD | -96.14% |
| 2009 | 103.37 Million USD | -11.69% |
| 2008 | 117.05 Million USD | -5.51% |
| 2007 | 123.88 Million USD | 6.89% |
| 2006 | 115.89 Million USD | 21.21% |
| 2005 | 95.61 Million USD | 31.02% |
| 2004 | 72.97 Million USD | 12.52% |
| 2003 | 64.85 Million USD | 11.37% |
| 2002 | 58.23 Million USD | 16.12% |
| 2001 | 50.15 Million USD | 69.92% |
| 2000 | 29.51 Million USD | 192.25% |
| 1999 | 10.1 Million USD | -9.01% |
| 1998 | 11.1 Million USD | 5.71% |
| 1997 | 10.5 Million USD | 38.16% |
| 1996 | 7.6 Million USD | 20.63% |
| 1995 | 6.3 Million USD | 320.0% |
| 1994 | 1.5 Million USD | 1400.0% |
| 1993 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 3000.00 USD | 0.0% |
| 2024 Q1 | 3000.00 USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 FY | 12 Thousand USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | 3000.00 USD | -66.67% |
| 2023 Q3 | 9000.00 USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | 12 Thousand USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | 12 Thousand USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2013 Q2 | 102.4 Thousand USD | 26.33% |
| 2013 Q3 | 139.98 Thousand USD | 36.7% |
| 2013 Q4 | 101.3 Thousand USD | -27.63% |
| 2013 Q1 | 81.05 Thousand USD | -56.71% |
| 2013 FY | 424.75 Thousand USD | -31.08% |
| 2012 FY | 616.33 Thousand USD | -83.65% |
| 2012 Q3 | 96.03 Thousand USD | -38.52% |
| 2012 Q1 | 709.87 Thousand USD | -13.69% |
| 2012 Q4 | 187.25 Thousand USD | 94.99% |
| 2012 Q2 | 156.21 Thousand USD | -77.99% |
| 2011 FY | 3.76 Million USD | -5.64% |
| 2011 Q3 | 860.62 Thousand USD | -22.87% |
| 2011 Q2 | 1.11 Million USD | 14.93% |
| 2011 Q1 | 970.87 Thousand USD | 101.24% |
| 2011 Q4 | 822.45 Thousand USD | -4.43% |
| 2010 Q2 | 33.61 Million USD | 44.31% |
| 2010 Q3 | 25.38 Million USD | -24.5% |
| 2010 Q4 | -78.3 Million USD | -408.5% |
| 2010 FY | 3.99 Million USD | -96.14% |
| 2010 Q1 | 23.29 Million USD | -22.24% |
| 2009 Q3 | 21.85 Million USD | -27.76% |
| 2009 Q2 | 30.25 Million USD | 41.94% |
| 2009 FY | 103.37 Million USD | -11.69% |
| 2009 Q1 | 21.31 Million USD | -26.55% |
| 2009 Q4 | 29.95 Million USD | 37.08% |
| 2008 FY | 117.05 Million USD | -5.51% |
| 2008 Q4 | 29.01 Million USD | 13.7% |
| 2008 Q3 | 25.52 Million USD | -31.14% |
| 2008 Q2 | 37.06 Million USD | 30.76% |
| 2008 Q1 | 28.34 Million USD | -8.66% |
| 2007 Q2 | 39.55 Million USD | 39.43% |
| 2007 Q1 | 28.37 Million USD | -20.63% |
| 2007 Q4 | 31.03 Million USD | 10.02% |
| 2007 FY | 123.88 Million USD | 6.89% |
| 2007 Q3 | 28.2 Million USD | -28.69% |
| 2006 Q3 | 26.03 Million USD | -21.12% |
| 2006 FY | 115.89 Million USD | 21.21% |
| 2006 Q4 | 35.74 Million USD | 37.27% |
| 2006 Q2 | 33.01 Million USD | 37.8% |
| 2006 Q1 | 23.95 Million USD | 4.89% |
| 2005 Q3 | 22.96 Million USD | -17.76% |
| 2005 FY | 95.61 Million USD | 31.02% |
| 2005 Q4 | 22.83 Million USD | -0.56% |
| 2005 Q2 | 27.92 Million USD | 27.59% |
| 2005 Q1 | 21.88 Million USD | -7.68% |
| 2004 Q1 | 14.78 Million USD | -23.57% |
| 2004 Q2 | 19.38 Million USD | 31.11% |
| 2004 Q4 | 23.7 Million USD | 56.97% |
| 2004 Q3 | 15.1 Million USD | -22.09% |
| 2004 FY | 72.97 Million USD | 12.52% |
| 2003 Q2 | 16.97 Million USD | 16.58% |
| 2003 Q3 | 13.97 Million USD | -17.68% |
| 2003 Q4 | 19.34 Million USD | 38.41% |
| 2003 FY | 64.85 Million USD | 11.37% |
| 2003 Q1 | 14.56 Million USD | -8.91% |
| 2002 Q1 | 12.91 Million USD | 1.01% |
| 2002 Q2 | 16.52 Million USD | 27.98% |
| 2002 Q4 | 15.98 Million USD | 24.74% |
| 2002 Q3 | 12.81 Million USD | -22.43% |
| 2002 FY | 58.23 Million USD | 16.12% |
| 2001 Q4 | 12.78 Million USD | 16.03% |
| 2001 FY | 50.15 Million USD | 69.92% |
| 2001 Q2 | 15.47 Million USD | 15.94% |
| 2001 Q1 | 13.35 Million USD | 16.05% |
| 2001 Q3 | 11.01 Million USD | -28.84% |
| 2000 Q4 | 11.5 Million USD | 43.3% |
| 2000 Q2 | 5.9 Million USD | 44.83% |
| 2000 FY | 29.51 Million USD | 192.25% |
| 2000 Q1 | 4.07 Million USD | -5.17% |
| 2000 Q3 | 8.02 Million USD | 35.96% |
| 1999 Q1 | 1.3 Million USD | -62.86% |
| 1999 Q4 | 4.3 Million USD | 53.57% |
| 1999 Q3 | 2.8 Million USD | 64.71% |
| 1999 Q2 | 1.7 Million USD | 30.77% |
| 1999 FY | 10.1 Million USD | -9.01% |
| 1998 FY | 11.1 Million USD | 5.71% |
| 1998 Q3 | 2.3 Million USD | -11.54% |
| 1998 Q2 | 2.6 Million USD | -3.7% |
| 1998 Q1 | 2.7 Million USD | -12.9% |
| 1998 Q4 | 3.5 Million USD | 52.17% |
| 1997 Q4 | 3.1 Million USD | 55.0% |
| 1997 Q3 | 2 Million USD | -45.95% |
| 1997 Q2 | 3.7 Million USD | 117.65% |
| 1997 Q1 | 1.7 Million USD | -32.0% |
| 1997 FY | 10.5 Million USD | 38.16% |
| 1996 Q1 | 1.5 Million USD | -11.76% |
| 1996 Q2 | 1.9 Million USD | 26.67% |
| 1996 FY | 7.6 Million USD | 20.63% |
| 1996 Q4 | 2.5 Million USD | 47.06% |
| 1996 Q3 | 1.7 Million USD | -10.53% |
| 1995 FY | 6.3 Million USD | 320.0% |
| 1995 Q1 | 1.6 Million USD | 14.29% |
| 1995 Q4 | 1.7 Million USD | 41.67% |
| 1995 Q3 | 1.2 Million USD | -33.33% |
| 1995 Q2 | 1.8 Million USD | 12.5% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q4 | 1.4 Million USD | 1300.0% |
| 1994 FY | 1.5 Million USD | 1400.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q2 | 100 Thousand USD | 0.0% |
| 1993 Q1 | 100 Thousand USD | 0.0% |
| 1993 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | 98.686% |
| Arrayit Corporation | 4.37 Million USD | 99.726% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 99.954% |
| Bioqual, Inc. | 58.59 Million USD | 99.98% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 99.922% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 100.0% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 99.812% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | 98.859% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 99.97% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | 97.318% |
| InVitro International | 792.62 Thousand USD | 98.486% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 99.892% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 99.834% |
| Optigenex Inc. | 465.97 Thousand USD | 97.425% |
| PharmChem, Inc. | 6.01 Million USD | 99.8% |
| Proteome Sciences plc | 6.4 Million USD | 99.813% |
| Response Genetics, Inc | 18.04 Million USD | 99.933% |
| Rennova Health, Inc. | 13.03 Million USD | 99.908% |
| RushNet, Inc. | 1.78 Million USD | 99.329% |
| ScreenPro Security Inc. | 1.91 Million USD | 99.373% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 99.684% |
| Todos Medical Ltd. | 7.69 Million USD | 99.844% |